Research article
Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
1 Genelux Corporation, San Diego Science Center, San Diego, California, USA
2 Virchow Center for Experimental Biomedicine and Institute for Biochemistry, University of Würzburg, Am Hubland, Würzburg, Germany
3 Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
4 Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, MO, USA
5 Cellular Processing Section, Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland, USA
6 Department of Pathology, Immunology Section, University of Verona Medical School, Verona, Italy
BMC Genomics 2009, 10:301 doi:10.1186/1471-2164-10-301
Published: 7 July 2009Additional files
Additional file 1:
Replication ability of GLV-1h68 in multiple human cancer cell lines. Viral titers were examined 24, 48 and 72 hpi in 13 human cancer cell lines representing highly susceptible and delayed in vitro replication models.
Format: PDF Size: 21KB Download file
This file can be viewed with: Adobe Acrobat Reader
Additional file 2:
Sequence verification of genes which have potentially cross hybridized between human and mouse arrays. The data provided represent the sequence analysis of selected genes which have been described as up regulated in infected GI-101A xenografts based on human 17 K cDNA arrays but not based on human 36 K oligo arrays. Some of the genes were in fact expressed by the host and cross-hybridized to less specific cDNA probes on the human platform.
Format: PDF Size: 47KB Download file
This file can be viewed with: Adobe Acrobat Reader
